Cambridge Heart's CH 2000 Cleared To Include SCA Prognostic Indication
This article was originally published in The Gray Sheet
Executive Summary
Cambridge Heart, Inc., expects its proprietary high-resolution electrode leads to generate additional revenue following FDA clearance of the CH 2000 T-wave alternans stress test 510(k) April 13 for the prognosis of sudden cardiac arrest.